Fluoguide AS
STO:FLUO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.9
75.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Pre-Tax Income
Fluoguide AS
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
F
|
Fluoguide AS
STO:FLUO
|
Pre-Tax Income
-kr43.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-283%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Pre-Tax Income
kr7.5B
|
CAGR 3-Years
35%
|
CAGR 5-Years
44%
|
CAGR 10-Years
50%
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Pre-Tax Income
-kr1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-36%
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Pre-Tax Income
-€416.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-66%
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Pre-Tax Income
kr715.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
CSE:BIOPOR
|
Pre-Tax Income
-kr55.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Pre-Tax Income?
Pre-Tax Income
-43.9m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Pre-Tax Income amounts to -43.9m DKK.
What is Fluoguide AS's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-283%
Over the last year, the Pre-Tax Income growth was -34%. The average annual Pre-Tax Income growth rates for Fluoguide AS have been -26% over the past three years , -283% over the past five years .